| 前收市價 | 45.65 |
| 開市 | 45.91 |
| 買盤 | 55.20 |
| 賣出價 | 58.80 |
| 拍板 | 175.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 45.65 - 45.91 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
ZacksDexCom's (DXCM) G6 CGM System Combines With AID in Netherlands
DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.
ZacksInsulet (PODD) Unveils Key Achievements for the Omnipod 5 System
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
InvestorPlaceThe 3 Best Diabetes Stocks to Buy in June 2024
Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they
